Email not displaying correctly? View it in your browser

Professor El Hassan on DNDi and the LEAP platform’s efforts to strengthen Sudan’s capacity to combat visceral leishmaniasis

Professor El Hassan from the Institute of Endemic Diseases, University of
Khartoum, explains how DNDi and the LEAP platform have endeavoured over
nearly a decade to bring change through capacity strengthening to the management and treatment of visceral leishmaniasis in Sudan.
Listen to podcast    


Registration of the antimalarial ASMQ FDC in Malaysia
After the registration of Artesunate/Mefloquine (ASMQ) fixed-dose combination in India in December 2011, Malaysia is the second country in Asia to register the antimalarial drug developed and launched by DNDi and its partners in 2008.
 Read more

DNDi and AstraZeneca sign agreement on drug screening for NTDs   

DNDi and AstraZeneca, following commitments announced at the London ‘Uniting to Combat NTDs’ event in January, have signed their first-ever agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness.
 Read more
Argentina launches benznidazole
Bernard Pécoul was invited by a consortium including Fundacion Mundo Sano, the Argentinian Ministry of Health, and two pharmaceutical companies (MAPRIMED and ELEA, of the CHEMO group) to launch  the production of benznidazole for Chagas in Argentina. Dr Pécoul speaks about his vist to Argentina, the event and the importance of a second source of the drug.
 Listen to Podcast 

Events: Geneva Health Forum 2012 

Giving a voice to the frontliners of health, this year's edition of the GHF focuses on chronic conditions. DNDi and MSF will co-host a session on adult chronic Chagas disease.
Read more